Patent ID: 11866731
Assignee: CHINEO MEDICAL TECHNOLOGY CO., LTD
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 8:
9. The isolated population of modified immune cell of claim 1, wherein said protein that, in an unmodified immune cell, elicits an immune cell inactivation signal upon binding to its ligand is selected from the group consisting of transforming growth factor-beta receptor (TGF-beta-R), programmed cell death 1 (PD-1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), B and T lymphocyte attenuator (BTLA), a killer immunoglobulin-like receptor (KIR), indoleamine 2,3-dioxygenase (IDO), lymphocyte activation gene-3 (LAG3), T cell immunoglobulin mucin 3 (TIM-3), and TIGIT.